6/28/2022 6:04:56 AM
IDEAYA Announces Selection Of Potential First-in-class Pol Theta Helicase Development Candidate
5/10/2022 6:13:10 AM
IDEAYA Biosciences Q1 Net Loss $14.0 Mln Vs Net Losss $18.2 Mln Last Year
5/2/2022 6:02:29 AM
IDEAYA Biosciences Receives Orphan Drug Designation For Darovasertib For Uveal Melanoma
3/16/2022 4:47:32 PM
Wedbush Is Increasing IDEAYA Biosciences (IDYA) FY22 Estimate To -1.66 From -1.69
3/16/2022 4:47:16 PM
Wedbush Is Raising IDEAYA Biosciences (IDYA) Q4 22 Estimate To -0.47 From -0.48
3/16/2022 4:47:03 PM
Wedbush Is Raising IDEAYA Biosciences (IDYA) Q3 22 Estimate To -0.43 From -0.44
3/16/2022 4:46:41 PM
Wedbush Is Raising IDEAYA Biosciences (IDYA) Q1 22 Estimate To -0.36 From -0.37
3/16/2022 4:46:09 PM
Wedbush Reiterates IDEAYA Biosciences (IDYA) At Outperform With $34 Price Target
3/15/2022 6:11:26 AM
IDEAYA Biosciences Q4 Net Loss $18.2 Mln Vs Loss $5.1 Mln Last Year
3/14/2022 6:06:10 AM
IDEAYA, Pfizer Enter Clinical Trial Collaboration Agreements For Evaluation Of Darovasertib And Crizotinib Combination
1/31/2022 6:04:16 AM
IDEAYA Biosciences Begins IND-enabling Studies For IDE161, A Potential PARG Inhibitor Development Candidate
1/5/2022 6:02:05 AM
IDEAYA Biosciences Announces Acquisition Of Proprietary INQUIRE Chemical Library
1/4/2022 6:02:07 AM
IDEAYA Biosciences Appoints Frank McCormick As Chair Of Scientific Advisory Board
12/7/2021 7:12:35 AM
IDEAYA Reports Data From Phase 2 Expansion Dose Of Darovasertib And Crizotinib Synthetic Lethal Combination In MUM
11/17/2021 4:37:08 PM
Wedbush Reiterates IDEAYA Biosciences (IDYA) At Outperform With $31 Price Target
11/15/2021 6:07:29 AM
IDEAYA Biosciences Q3 Net Loss Widens To $11.6 Mln From $10.9 Mln Last Year